Document Type
Article
Publication Date
2016
DOI
10.15761/BRCP.1000103
Publication Title
Biomedical Research and Clinical Practice
Volume
1
Issue
1
Pages
7-15
Abstract
((E)-2-(2-hydroxybenzylideneamino)phenolato-2,2-diphenyl-6-aza-1,3-dioxa-2-stanna-[d,h]dibenzocyclononene, [Sn(Ph₂SB)] (compound 1, where Ph₂SB=(E)-2-(2-hydroxybenzylideneamino)phenolato Schiff base) and two novel compounds, [[SnPh2(F-azoSB)] (compound 2, where F-azoSB=4-((E)-(4-fluorophenyl)diazenyl)-2-((E)-(2-hydroxyphenylimino)methyl)phenolato Schiff base), [[SnPh2(sulf-azoSB)]0.125CHCl₃ (compound 3, where sulfamerazineazosalSB=4-((E)-(4-hydroxy-3-((E)-(2-hydroxyphenylimino)methyl)phenyl)diazenyl)-N-(4-methylpyrimidin-2-yl) benzenesulfonamide Schiff base), and the control compound, cisplatin (compound 4) were analysed to comparatively determine their effect on cancer cell growth. Anti-cancer properties of compounds 1-4 were examined using glioblastoma (U-1242 MG), colorectal (HT-29 and HCT-116), and skin (A431) human cancer cell lines. With regards to human glioblastoma cells, compounds 1 and 3 demonstrated anti-proliferative capacity in the cell line tested. Specifically, compounds 1 and 3 inhibited cell proliferation by 50% at concentrations between 10 and 50 µM. With respect to colon cancer cell lines, the IC₅₀ values for compounds 1-3 ranged from 3.04 ± 0.98 to 104.51 ± 13.87 mM. In the case of HCT116, this translates to a 3- to 73-fold inhibitory effect of compounds 1-3 over cisplatin. In all cell lines tested, the chemo-effect was more pronounced with compounds 1-3 than with the control (compound 4); demonstrating that these azo-containing Sn(IV) complexes were more potent than compound 4. The overall effect of compounds 1-3 in the induction of appotosis and the inhibition of proliferation have defined an essential role for these compounds in chemotherapy.
Rights
© 2016 Williams JL.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Original Publication Citation
Williams, J. L., Lewis-Alleyne, L. C., Solomon, M., Nguyen, L., Johnson, R., Vital, J., Ji, P., Durant, J., Cooper, C., Cagle, P., Martin, P., VanDerveer, D., Jarrett, W. L., & Holder, A. A. (2016). An in vitro study on the effect of synthesized tin (IV) complexes on glioblastoma, colorectal, and skin cancer cell lines. Biomedical Research and Clinical Practice, 1(1), 7-15. https://doi.org/10.15761/BRCP.1000103
ORCID
0000-0001-9618-5297 (Holder)
Repository Citation
Williams, Jennie L.; Lewis-Alleyne, Lesley C.; Solomon, Melinda; Nguyen, Long; Johnson, Robert; Vital, Jennifer; Ji, Ping; Durant, John; Cooper, Camille; Cagle, Patrice; Martin, Patrick; VanDerveer, Don; Jarrett, William L.; and Holder, Alvin A., "An in vitro Study on the Effect of Synthesized tin (IV) Complexes on Glioblastoma, Colorectal, and Skin Cancer Cell Lines" (2016). Chemistry & Biochemistry Faculty Publications. 336.
https://digitalcommons.odu.edu/chemistry_fac_pubs/336